跳至主要内容
临床试验/ISRCTN26863825
ISRCTN26863825已完成未知

Trial of CHOP versus CIOP in Good Risk Stage II-IV Patients with Histologically Aggressive Non-Hodgkin's Lymphoma

British National Lymphoma Investigation (BNLI) (UK)0 个研究点目标入组 211 人开始时间: 2002年8月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
211

研究概览

简要总结

2005 results in: https://www.ncbi.nlm.nih.gov/pubmed/16098067 (added 31/10/2019)

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age 16-59 years
  • 2. No medical conditions, other than lymphoma, prohibiting intensive therapy and no systemic treatment for cancer in previous 5 years
  • 3. One of the following histological types:
  • 3.1 Follicular large cell
  • 3.2 Diffuse mixed cell
  • 3.3 Diffuse large cell
  • 3.4 Diffuse immunoblastic lymphomas
  • 4. Full clinical staging to include Computed Tomography (CT) scanning of abdomen and bone marrow trephine biopsy
  • 5. Good prognostic features defined as the presence of less than two of:
  • 5.1 Stage III/IV
  • 5.2 Lactic dehydrogenase (LDH) >normal
  • 5.3 Eastern Cooperative Oncology Group (ECOG) or World Health Organisation (WHO) performance status 2-4

排除标准

  • Not provided at time of registration

研究者

发起方
British National Lymphoma Investigation (BNLI) (UK)

相似试验